Group 1 - The core viewpoint of the article emphasizes the critical role of non-human primates, particularly monkeys, in the drug development process, highlighting their necessity in preclinical trials and the increasing demand for them due to the surge in pharmaceutical research [4][10][24] - The cost of developing a new drug is substantial, with estimates indicating that it can reach up to $25.58 billion when accounting for capital time and opportunity costs [1] - The demand for experimental monkeys surged during the COVID-19 pandemic, leading to a dramatic increase in their prices, with some reaching as high as 230,000 yuan (approximately $35,000) per monkey in 2020 [12][14][20] Group 2 - The supply of experimental monkeys is constrained by their slow reproduction rates and the high standards required for them to be used in research, which has led to a significant supply-demand imbalance [18][28] - China is the largest producer and exporter of experimental monkeys, with a significant portion of the global supply coming from this region, particularly before the export ban implemented during the pandemic [26][28] - The classification of the crab-eating macaque as an endangered species by the IUCN has raised concerns about the future availability of these primates for research, as international trade regulations will become stricter [24][28]
猴子,如何成了国家战略资源?
3 6 Ke·2025-09-15 08:26